ReviewJournal of thoracic disease2022
A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 4: systematic review of evidence involving SBRT and ablation.
Review in Journal of thoracic disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Bronchoscopic Ablation and Intratumoral Therapies for Lung Cancer: Expanding Local Treatment Beyond Surgical Resection.Cancers · 2026Review
- Impact of thoracoscopic segmental lung resection versus wedge on early post-operative recovery and short-term prognosis in elderly patients with early non-small cell lung cancer: A retrospective non-randomised controlled cohort study.Journal of minimal access surgery · 2026Article
- Advances in Percutaneous and Endovascular Locoregional Therapies for Primary and Metastatic Lung Cancer.Cancers · 2026Review
- Nationwide trends in radiotherapy use among older patients with early-stage non-small cell lung cancer in Japan, 2013-2022.Scientific reports · 2026Article
- The evolving role of wedge resection in early-stage non-small cell lung cancer: a literature review.Translational lung cancer research · 2025Review
- Current evidence and ongoing trials for surgery versus stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer: a narrative review.Translational lung cancer research · 2025Review
- Stereotactic body radiotherapy for early‑stage non‑small cell lung cancer: Comprehensive analysis of outcomes and recurrence from a single‑center experience.Oncology letters · 2025Article
- CyberKnifeJournal of thoracic disease · 2023Article
- Lung cancer with air lucency: a systematic review and clinical management guide.Journal of thoracic disease · 2023Review
- Planning issues on linac-based stereotactic radiotherapy.World journal of clinical cases · 2022Review
- Local tumour residue after microwave ablation for lung cancer: a case report.Interactive cardiovascular and thoracic surgery · 2022Article
- The quality of systematic reviews on the treatment of stage I non-small cell lung cancer for individualized decision-making: improved but further refinements are needed.Journal of thoracic disease · 2022Article
- The more we learn, the more there is to know: the clinical management of stage I non-small cell lung cancer.Journal of thoracic disease · 2022Article
- Resect a little, resect more, irradiate or ablate-what is the best approach?Journal of thoracic disease · 2022Article
- A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 2: systematic review of evidence regarding resection extent in generally healthy patients.Journal of thoracic disease · 2022Review
- A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors.Journal of thoracic disease · 2022Review
- A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 1: a guide to decision-making.Journal of thoracic disease · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Background: Clinical decision-making for patients with stage I lung cancer is complex. It involves multiple options [lobectomy, segmentectomy, wedge, stereotactic body radiotherapy (SBRT), thermal ablation], weighing multiple outcomes (e.g., short-, intermediate-, long-term) and multiple aspects of each (e.g., magnitude of a difference, the degree of confidence in the evidence, and the applicability to the patient and setting at hand). A structure is needed to summarize the relevant evidence for an individual patient and to identify which outcomes have the greatest impact on the decision-making. Methods: A PubMed systematic review from 2000-2021 of outcomes after SBRT or thermal ablation Results: Short-term outcomes are meaningfully better after SBRT than resection. SBRT doesn't affect quality-of-life (QOL), on average pulmonary function is not altered, but a minority of patients may experience gradual late toxicity. Adjusted non-randomized comparisons demonstrate a clinically relevant detriment in long-term outcomes after SBRT Conclusions: A systematic, comprehensive summary of evidence regarding Stereotactic Body Radiotherapy or thermal ablation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.